SHANGHAI, May 24, 2023 /PRNewswire/ — BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the Investigational New Drug (IND) application for the clinical trial of its proprietary BRY812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.